Skip to content
Trial Eligibility
Menu

A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07946575

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Healthy Participants

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 to 60 years
Sex
All
Healthy volunteers
Accepted
Sponsor
Trevi Therapeutics
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Florida · 1

  • Clinical Pharmacology of Miami, LLC · Miami, FL

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.